<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01143389</url>
  </required_header>
  <id_info>
    <org_study_id>2010-0243</org_study_id>
    <nct_id>NCT01143389</nct_id>
  </id_info>
  <brief_title>Corneal Crosslinking in Patients With Keratoconus and Post-Refractive Ectasia</brief_title>
  <official_title>Evaluation of Two Riboflavin Dosing Regimens for Corneal Collagen Cross-Linking in Eyes With Progressive Keratoconus or Ectasia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Price Vision Group</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Price Vision Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effectiveness of using riboflavin and UV light
      to treat progressive keratoconus or post-refractive corneal ectasia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of this study is to evaluate two riboflavin-dosing regimens for corneal
      collagen cross-linking to slow the progressive changes in corneal curvature in eyes with
      progressive keratoconus or post-refractive ectasia.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2010</start_date>
  <completion_date type="Actual">August 30, 2017</completion_date>
  <primary_completion_date type="Actual">May 30, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Maximum Keratometry From Baseline to 6 Months After Treatment</measure>
    <time_frame>6 months</time_frame>
    <description>Change in maximum keratometry (Kmax) between baseline and 6 months after treatment, measured by corneal tomography.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pachymetry</measure>
    <time_frame>6 months</time_frame>
    <description>Minimum corneal thickness measured by corneal tomography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Corrected Distance Visual Acuity (CDVA)</measure>
    <time_frame>6 months</time_frame>
    <description>Corrected distance visual acuity (CDVA) reported in logarithm of the minimum angle of resolution (logMAR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Uncorrected Distance Visual Acuity (UDVA)</measure>
    <time_frame>6 months</time_frame>
    <description>Uncorrected distance visual acuity reported in logarithm of the minimum angle of resolution units</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">510</enrollment>
  <condition>Keratoconus</condition>
  <condition>Post-Refractive Ectasia</condition>
  <arm_group>
    <arm_group_label>Riboflavin 0.1% eyedrops every 5 minutes</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The eye will be irradiated for 30 minutes with UVX light, during which time instillation of riboflavin will continue (1 drop every 5 minutes for this arm).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Riboflavin 0.1% eyedrops every 2 minutes</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The eye will be irradiated for 30 minutes with UVX light, during which time instillation of riboflavin will continue (1 drop every 2 minutes for this arm).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Riboflavin</intervention_name>
    <description>Riboflavin 0.1% eye drops are applied before and during irradiation of the cornea.</description>
    <arm_group_label>Riboflavin 0.1% eyedrops every 5 minutes</arm_group_label>
    <arm_group_label>Riboflavin 0.1% eyedrops every 2 minutes</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>UVX light</intervention_name>
    <description>UVX 365 nm wavelength light source is applied with continued application of riboflavin.</description>
    <arm_group_label>Riboflavin 0.1% eyedrops every 5 minutes</arm_group_label>
    <arm_group_label>Riboflavin 0.1% eyedrops every 2 minutes</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. 10 years of age or older

          2. Having documented ectasia on topography or tomography after previous refractive
             surgery OR progressive keratoconus defined as one or more of the following changes
             over a period of 36 months or less before randomization:

               1. An increase of ≥ 1.00 D in the steepest keratometry value (or sim K)

               2. An increase of ≥ 1.00 D in regular astigmatism evaluated by subjective manifest
                  refraction

               3. A myopic shift (decrease in the spherical equivalent) of ≥ 0.50 D on subjective
                  manifest refraction

               4. Documented decrease in visual acuity associated with irregular astigmatism and
                  topographic features of ectasia.

          3. Subjects with keratoconus diagnosis only:

             a. Axial topography consistent with keratoconus b. Presence of central or inferior
             steepening on the Pentacam map. c. Presence of one or more slit lamp findings
             associated with keratoconus, such as: i. Fleischer ring ii. Vogt striae iii. Corneal
             thinning iv. Corneal scarring

          4. Contact Lens Wearers Only: Removal of contact lenses for the required period of time
             prior to the screening refraction:

             Contact Lens Type Minimum Discontinuation Time Soft 3 Days Soft Extended Wear 1 Week
             Soft Toric 2 Weeks Rigid gas permeable 2 Weeks

          5. Signed written informed consent

        Exclusion Criteria:

          -  1. Any keratoconus patient over 21 years of age without evidence of progression of his
             corneal deformity.

             2. Patients with excessively thin corneas. 3. Previous ocular condition in the eyes to
             be treated that may predispose the eye for future complications, for example:

             a. History of corneal disease (e.g., herpes simplex, herpes zoster keratitis,
             recurrent erosion syndrome, corneal melt, corneal dystrophy, etc.) b. Clinically
             significant corneal scarring in the proposed treatment zone 4. A history of chemical
             injury or delayed epithelial healing in the eye(s) to be treated.

             5. A known sensitivity to treatment medications. 6. Patients with a current condition
             that, in the treating physician's opinion, would interfere with or prolong epithelial
             healing.

             7. Pregnancy (including plan to become pregnant) or lactation during the course of the
             study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Francis W Price, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Price Vision Group</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Price Vision Group</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46260</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.pricevisiongroup.com/</url>
    <description>Price Vision Group Website</description>
  </link>
  <reference>
    <citation>Wittig-Silva C, Whiting M, Lamoureux E, Lindsay RG, Sullivan LJ, Snibson GR. A randomized controlled trial of corneal collagen cross-linking in progressive keratoconus: preliminary results. J Refract Surg. 2008 Sep;24(7):S720-5.</citation>
    <PMID>18811118</PMID>
  </reference>
  <reference>
    <citation>Raiskup-Wolf F, Hoyer A, Spoerl E, Pillunat LE. Collagen crosslinking with riboflavin and ultraviolet-A light in keratoconus: long-term results. J Cataract Refract Surg. 2008 May;34(5):796-801. doi: 10.1016/j.jcrs.2007.12.039.</citation>
    <PMID>18471635</PMID>
  </reference>
  <reference>
    <citation>Mazzotta C, Traversi C, Baiocchi S, Sergio P, Caporossi T, Caporossi A. Conservative treatment of keratoconus by riboflavin-uva-induced cross-linking of corneal collagen: qualitative investigation. Eur J Ophthalmol. 2006 Jul-Aug;16(4):530-5.</citation>
    <PMID>16952090</PMID>
  </reference>
  <reference>
    <citation>Caporossi A, Baiocchi S, Mazzotta C, Traversi C, Caporossi T. Parasurgical therapy for keratoconus by riboflavin-ultraviolet type A rays induced cross-linking of corneal collagen: preliminary refractive results in an Italian study. J Cataract Refract Surg. 2006 May;32(5):837-45.</citation>
    <PMID>16765803</PMID>
  </reference>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 11, 2010</study_first_submitted>
  <study_first_submitted_qc>June 11, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 14, 2010</study_first_posted>
  <results_first_submitted>April 3, 2018</results_first_submitted>
  <results_first_submitted_qc>April 3, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">May 4, 2018</results_first_posted>
  <last_update_submitted>April 3, 2018</last_update_submitted>
  <last_update_submitted_qc>April 3, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 4, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Keratoconus</keyword>
  <keyword>Ectasia</keyword>
  <keyword>cross linking</keyword>
  <keyword>collagen cross linking</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Keratoconus</mesh_term>
    <mesh_term>Dilatation, Pathologic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Riboflavin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Riboflavin 0.1% Eyedrops Every 5 Minutes</title>
          <description>The eye will be irradiated for 30 minutes with UVX light, during which the instillation of riboflavin will continue (1 drop every 5 minutes for this arm).
Riboflavin: Riboflavin 0.1% eye drops are applied before and during irradiation of the cornea.
UVX light: UVX 365 nm wavelength light source is applied with continued application of riboflavin.</description>
        </group>
        <group group_id="P2">
          <title>Riboflavin 0.1% Eyedrops Every 2 Minutes</title>
          <description>The eye will be irradiated for 30 minutes with UVX light, during which the instillation of riboflavin will continue (1 drop every 2 minutes for this arm).
Riboflavin: Riboflavin 0.1% eye drops are applied before and during irradiation of the cornea.
UVX light: UVX 365 nm wavelength light source is applied with continued application of riboflavin.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="253"/>
                <participants group_id="P2" count="257"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="227"/>
                <participants group_id="P2" count="232"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="25"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="25"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Riboflavin 0.1% Eyedrops Every 5 Minutes</title>
          <description>The eye will be irradiated for 30 minutes with UVX light, during which time instillation of riboflavin will continue (1 drop every 5 minutes for this arm).
Riboflavin: Riboflavin 0.1% eye drops are applied before and during irradiation of the cornea.
UVX light: UVX 365 nm wavelength light source is applied with continued application of riboflavin.</description>
        </group>
        <group group_id="B2">
          <title>Riboflavin 0.1% Eyedrops Every 2 Minutes</title>
          <description>The eye will be irradiated for 30 minutes with UVX light, during which time instillation of riboflavin will continue (1 drop every 2 minutes for this arm).
Riboflavin: Riboflavin 0.1% eye drops are applied before and during irradiation of the cornea.
UVX light: UVX 365 nm wavelength light source is applied with continued application of riboflavin.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="253"/>
            <count group_id="B2" value="257"/>
            <count group_id="B3" value="510"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32" spread="12"/>
                    <measurement group_id="B2" value="32" spread="13"/>
                    <measurement group_id="B3" value="32" spread="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="62"/>
                    <measurement group_id="B2" value="61"/>
                    <measurement group_id="B3" value="123"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="191"/>
                    <measurement group_id="B2" value="196"/>
                    <measurement group_id="B3" value="387"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="52"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="215"/>
                    <measurement group_id="B2" value="220"/>
                    <measurement group_id="B3" value="435"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="253"/>
                    <measurement group_id="B2" value="257"/>
                    <measurement group_id="B3" value="510"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Keratoconus/ectasia classification</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Keratoconus mild (flat K &lt;51D and astigmatism &lt;8D)</title>
                  <measurement_list>
                    <measurement group_id="B1" value="140"/>
                    <measurement group_id="B2" value="139"/>
                    <measurement group_id="B3" value="279"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Keratoconus moderate</title>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                    <measurement group_id="B2" value="43"/>
                    <measurement group_id="B3" value="86"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Keratoconus severe (flat K &gt;56D by tomography)</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="41"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Ectasia after refractive surgery</title>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                    <measurement group_id="B2" value="54"/>
                    <measurement group_id="B3" value="104"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Maximum Keratometry From Baseline to 6 Months After Treatment</title>
        <description>Change in maximum keratometry (Kmax) between baseline and 6 months after treatment, measured by corneal tomography.</description>
        <time_frame>6 months</time_frame>
        <population>Per protocol population</population>
        <group_list>
          <group group_id="O1">
            <title>Riboflavin 0.1% Eyedrops Every 5 Minutes</title>
            <description>The eye will be irradiated for 30 minutes with UVX light, during which the instillation of riboflavin will continue (1 drop every 5 minutes for this arm).
Riboflavin: Riboflavin 0.1% eye drops are applied before and during irradiation of the cornea.
UVX light: UVX 365 nm wavelength light source is applied with continued application of riboflavin.</description>
          </group>
          <group group_id="O2">
            <title>Riboflavin 0.1% Eyedrops Every 2 Minutes</title>
            <description>The eye will be irradiated for 30 minutes with UVX light, during which the instillation of riboflavin will continue (1 drop every 2 minutes for this arm).
Riboflavin: Riboflavin 0.1% eye drops are applied before and during irradiation of the cornea.
UVX light: UVX 365 nm wavelength light source is applied with continued application of riboflavin.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Maximum Keratometry From Baseline to 6 Months After Treatment</title>
          <description>Change in maximum keratometry (Kmax) between baseline and 6 months after treatment, measured by corneal tomography.</description>
          <population>Per protocol population</population>
          <units>diopters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="227"/>
                <count group_id="O2" value="232"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.76" spread="2.4"/>
                    <measurement group_id="O2" value="0.97" spread="3.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pachymetry</title>
        <description>Minimum corneal thickness measured by corneal tomography</description>
        <time_frame>6 months</time_frame>
        <population>Per protocol</population>
        <group_list>
          <group group_id="O1">
            <title>Riboflavin 0.1% Eyedrops Every 5 Minutes</title>
            <description>The eye will be irradiated for 30 minutes with UVX light, during which the instillation of riboflavin will continue (1 drop every 5 minutes for this arm).
Riboflavin: Riboflavin 0.1% eye drops are applied before and during irradiation of the cornea.
UVX light: UVX 365 nm wavelength light source is applied with continued application of riboflavin.</description>
          </group>
          <group group_id="O2">
            <title>Riboflavin 0.1% Eyedrops Every 2 Minutes</title>
            <description>The eye will be irradiated for 30 minutes with UVX light, during which the instillation of riboflavin will continue (1 drop every 2 minutes for this arm).
Riboflavin: Riboflavin 0.1% eye drops are applied before and during irradiation of the cornea.
UVX light: UVX 365 nm wavelength light source is applied with continued application of riboflavin.</description>
          </group>
        </group_list>
        <measure>
          <title>Pachymetry</title>
          <description>Minimum corneal thickness measured by corneal tomography</description>
          <population>Per protocol</population>
          <units>microns</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="227"/>
                <count group_id="O2" value="232"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="438" spread="51"/>
                    <measurement group_id="O2" value="434" spread="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Corrected Distance Visual Acuity (CDVA)</title>
        <description>Corrected distance visual acuity (CDVA) reported in logarithm of the minimum angle of resolution (logMAR)</description>
        <time_frame>6 months</time_frame>
        <population>Per protocol</population>
        <group_list>
          <group group_id="O1">
            <title>Riboflavin 0.1% Eyedrops Every 5 Minutes</title>
            <description>The eye will be irradiated for 30 minutes with UVX light, during which the instillation of riboflavin will continue (1 drop every 5 minutes for this arm).
Riboflavin: Riboflavin 0.1% eye drops are applied before and during irradiation of the cornea.
UVX light: UVX 365 nm wavelength light source is applied with continued application of riboflavin.</description>
          </group>
          <group group_id="O2">
            <title>Riboflavin 0.1% Eyedrops Every 2 Minutes</title>
            <description>The eye will be irradiated for 30 minutes with UVX light, during which the instillation of riboflavin will continue (1 drop every 2 minutes for this arm).
Riboflavin: Riboflavin 0.1% eye drops are applied before and during irradiation of the cornea.
UVX light: UVX 365 nm wavelength light source is applied with continued application of riboflavin.</description>
          </group>
        </group_list>
        <measure>
          <title>Corrected Distance Visual Acuity (CDVA)</title>
          <description>Corrected distance visual acuity (CDVA) reported in logarithm of the minimum angle of resolution (logMAR)</description>
          <population>Per protocol</population>
          <units>logMAR</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="227"/>
                <count group_id="O2" value="232"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.32" spread="0.29"/>
                    <measurement group_id="O2" value="0.31" spread="0.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Uncorrected Distance Visual Acuity (UDVA)</title>
        <description>Uncorrected distance visual acuity reported in logarithm of the minimum angle of resolution units</description>
        <time_frame>6 months</time_frame>
        <population>Per protocol</population>
        <group_list>
          <group group_id="O1">
            <title>Riboflavin 0.1% Eyedrops Every 5 Minutes</title>
            <description>The eye will be irradiated for 30 minutes with UVX light, during which the instillation of riboflavin will continue (1 drop every 5 minutes for this arm).
Riboflavin: Riboflavin 0.1% eye drops are applied before and during irradiation of the cornea.
UVX light: UVX 365 nm wavelength light source is applied with continued application of riboflavin.</description>
          </group>
          <group group_id="O2">
            <title>Riboflavin 0.1% Eyedrops Every 2 Minutes</title>
            <description>The eye will be irradiated for 30 minutes with UVX light, during which the instillation of riboflavin will continue (1 drop every 2 minutes for this arm).
Riboflavin: Riboflavin 0.1% eye drops are applied before and during irradiation of the cornea.
UVX light: UVX 365 nm wavelength light source is applied with continued application of riboflavin.</description>
          </group>
        </group_list>
        <measure>
          <title>Uncorrected Distance Visual Acuity (UDVA)</title>
          <description>Uncorrected distance visual acuity reported in logarithm of the minimum angle of resolution units</description>
          <population>Per protocol</population>
          <units>logMAR</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="227"/>
                <count group_id="O2" value="232"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.95" spread="0.53"/>
                    <measurement group_id="O2" value="0.91" spread="0.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Riboflavin 0.1% Eyedrops Every 5 Minutes</title>
          <description>The eye will be irradiated for 30 minutes with UVX light, during which the instillation of riboflavin will continue (1 drop every 5 minutes for this arm).
Riboflavin: Riboflavin 0.1% eye drops are applied before and during irradiation of the cornea.
UVX light: UVX 365 nm wavelength light source is applied with continued application of riboflavin.</description>
        </group>
        <group group_id="E2">
          <title>Riboflavin 0.1% Eyedrops Every 2 Minutes</title>
          <description>The eye will be irradiated for 30 minutes with UVX light, during which the instillation of riboflavin will continue (1 drop every 2 minutes for this arm).
Riboflavin: Riboflavin 0.1% eye drops are applied before and during irradiation of the cornea.
UVX light: UVX 365 nm wavelength light source is applied with continued application of riboflavin.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="257"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="253"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="257"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Loss of 2 or more logMAR lines of corrected distance visual acuity (CDVA) relative to baseline</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="253"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="257"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Limitations included the 6-month follow up duration and the reduced reproducibility of measurement techniques in eyes with ectasia as compared with normal eyes.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Marianne Price, PhD</name_or_title>
      <organization>Cornea Research Foundation of America</organization>
      <phone>317-814-2990</phone>
      <email>mprice@cornea.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

